Connect with us

Technology

Fosun Pharma Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation

Published

on

SHANGHAI, Feb. 17, 2025 /PRNewswire/ — Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transformative potential of AI technology in the pharmaceutical and healthcare sectors. The company actively embraces AI technology, deploying it in areas such as drug research and development, medical imaging, and precision medicine through both independent research and external collaborations, thereby driving transformation and development in the pharmaceutical industry through technological advancements. At the same time, Fosun Pharma is accelerating the deeper application of AI technology in marketing, customer service, and smart office solutions, using AI to improve quality and efficiency while promoting enhanced corporate management effectiveness.

Self-developed PharmAID Decision Intelligence Platform Integrates Global Leading Large Model Technology and Has connected with Deepseek R1

As a pioneer in the AI transformation of the pharmaceutical industry, Fosun Pharma recently launched its self-developed PharmAID decision intelligence platform internally. This platform establishes a full lifecycle intelligent decision-making network covering innovative R&D scenarios. Deeply integrated with global leading large model technologies, the platform has taken the lead in connecting to with Deepseek R1. Based on the PharmAID decision intelligence platform, Fosun Pharma is accelerating the development of “drug commercial value-assisted decision-making” capabilities, broadening decision-making perspectives, and improving decision accuracy. The platform enhances drug R&D efficiency and accelerates the transformation of R&D achievements by integrating point prediction, conformational prediction, binding mechanism analysis, toxicology optimization, medical writing, and clinical information extraction. This initiative aims to lead innovation and transformation, and it is the first self-developed AI decision intelligence platform in pharmaceutical industry.

The PharmAID decision intelligence platform offers AI translation and AI medical writing/revision features, significantly improving information retrieval and writing efficiency under the support of AI technology. At present, the PharmAID decision intelligence platform has integrated multiple professional clinical information and pipeline data platforms around the world, increasing content generation accuracy in the pharmaceutical and healthcare field by 50% compared to general large models, with data updated at T+1, ensuring outstanding accuracy and timeliness. Moreover, Fosun Pharma applies AI technology to carry out intelligent training for sales personnel and further assists business scenarios, achieving “more precise” marketing. Through the deep empowerment of the PharmAID decision intelligence platform, Fosun Pharma is building its digital competitiveness, leading the entire pharmaceutical industry into a new era of AI-driven innovation.

AI Technology Empowers Innovative R&D and Accelerate Breakthroughs

Fosun Pharma actively promotes AI-driven innovation. As early as 2022, Fosun Pharma formed a strategic partnership with AI pharmaceutical company Insilico Medicine, combining strengths to embark on a new journey in global AI drug R&D. In January 2025, Henlius, a subsidiary of Fosun Pharma, entered into a strategic collaboration with DP Technology for AI-assisted drug R&D, aiming to integrate AI with physical modeling to jointly advance new drug development processes. This collaboration leverages DP Technology’s technical strength and project experience in the “AI for Science” field, combining expertise in drug discovery and AI computing to provide new insights for the development of biologics antibodies/ADCs and small molecule drugs targeting difficult-to-drug targets.

Building an “AI+X” Smart Healthcare Ecosystem

In medical devices sector, Fosun Aitrox, a subsidiary of Fosun Pharma, focuses on the medical AI field and is one of the few companies in China offering comprehensive AI medical service solutions across multiple departments including radiology, pathology, ultrasound, cardiology, respiratory, orthopedics, neurology, and thyroid and breast surgery. Fosun Aitrox delves into medical institutions and primary healthcare service scenarios, identifying real needs and enhancing service capabilities in core scenarios of tiered healthcare systems, including early screening, remote diagnosis, and precision medicine. Through the “AI+X” model, Fosun Aitrox collaborates deeply with top medical centers, promoting the transformation of scientific research achievements and the popularization of standardized medical systems, empowering the construction of smart diagnosis and treatment systems. Its three major AI-assisted diagnostic product lines—radiology imaging, pathology imaging, and ultrasound imaging—have been widely used clinically and have won multiple world championships in international competitions.

Fosun Aitrox’s AI medical imaging products can quickly and accurately analyze medical imaging data, providing doctors with diagnostic suggestions, helping them more efficiently identify lesions and assess conditions, thereby improving diagnostic accuracy and timeliness. The application of this technology not only enhances the quality and efficiency of medical services but also benefits patients in remote and resource-scarce areas, allowing them to access high-quality medical services locally. To date, Fosun Aitrox has expanded its presence to cover 70% of China, with operating businesses in over 20 provinces, establishing nearly 10 regional smart healthcare project models. The company has released and is developing more than 70 AI products.

Additionally, Fosun Pharma’s incubated company, JeDiCare, leverages its extensive experience in image navigation algorithm development and interventional consumable design, along with a global perspective, to innovatively introduce AR navigation technology into minimally invasive surgery. Its self-developed puncture surgery navigation device (AR navigation puncture positioning system) is currently under market application review. This product features proprietary “monocular vision augmented reality” technology, integrating computer vision monocular tracking and AR display technology, not only achieving precise positioning but also optimizing the positioning process. In the future, with the assistance of the AR navigation puncture positioning system, primary hospitals will also be able to perform precise thoracoscopic surgeries, bringing high-quality medical care to more patients.

Looking ahead, Fosun Pharma will continue to increase investment and exploration in AI, accelerating the construction of AI innovation across the entire industry chain through independent research and external collaborations, leading the AI transformation of the pharmaceutical industry, and contributing more wisdom and strength to the cause of human health.

***

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma’s innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of “Innovation for Good Health”, continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation.

For more information, please visit our official website: www.fosunpharma.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fosun-pharmaceutical-deeply-embraces-ai-self-developed-pharmaid-decision-intelligence-platform-boosts-efficient-innovation-302377891.html

SOURCE Fosun Pharma

Continue Reading

Technology

Saigon Technology: Why Businesses Fear Modernizing Software in the AI Era

Published

on

By

SYDNEY, Nov. 4, 2026 /PRNewswire/ — Modernizing an entire software system often leaves businesses with two choices: invest heavily in an in-house team for a project that may not require the same resources later, or work with an experienced partner that already has the expertise in place.

While outsourcing offers greater flexibility, it also raises concerns about data security, business disruption, and finding a partner capable of handling complex systems.

Saigon Technology, an award-winning software engineering company with an AI-native delivery approach, believes businesses shouldn’t have to sacrifice security or stability to modernize. With the right partner, they can move forward while keeping everything under control.

66% of Australian Enterprises Lack Full Data Access Visibility

At many businesses, the existing systems may hold customer records, financial data, and core business processes. Giving a partner full access can create risks that businesses are not willing to take.

But modernization does not always require handing over the keys to the entire system.

Instead, companies can limit access to specific parts of their software, keep sensitive data in protected environments, and require approval before major changes are made. External engineers can work with test data or selected modules while the business keeps control of its main systems.

This allows businesses to gain the skills they need without giving up oversight of their most valuable technology assets.

Then Comes the Fear of Disruption

Data security is only half the concern. What happens if a system upgrade interrupts orders, payments, or customer services? For businesses that rely on software every day, even a short disruption can affect customers, staff, and revenue.

Yet upgrading software does not always mean shutting down the old system and moving everything to a new one overnight.

A safer approach is to make changes step by step. Parts of the system can be upgraded while the rest continues running. Old and new systems may also run side by side, giving teams time to test changes, check data, and fix issues before a full switch.

With clear backup and recovery plans, businesses can reduce risk and maintain essential services throughout the process.

The Way Forward: Modernize Without Losing Control

These concerns raise a key question: how can businesses move faster without taking on more risk? The answer lies in choosing a development partner that works within the client’s rules, rather than asking the client to give up control.

Saigon Technology takes a security-focused approach to enterprise software modernization. Depending on project needs, its engineering teams can apply multi-factor authentication (2FA), data encryption, VPN-secured access, and role-based permissions to protect sensitive information. With 3 development centers in Vietnam, the company also brings the engineering expertise and capacity needed to upgrade critical systems while minimizing disruption to daily operations.

Saigon Technology holds ISO/IEC 27001:2022 certification for information security management and ISO 9001:2015 certification for quality management, reinforcing its commitment to secure software delivery.

“Businesses should not have to choose between keeping their systems safe and moving forward with new technology. A good engineering partner helps them do both, without putting daily operations at unnecessary risk.” Shared by Thanh Pham, CEO of Saigon Technology.

As AI creates new opportunities, Saigon Technology believes the businesses best placed to benefit will be those that can embrace change without losing control of what already works.

About Saigon Technology

Saigon Technology is an AI-driven software engineering company with over 400 engineers. Serving clients across Australia and global markets, the company combines AI expertise, secure engineering, and flexible delivery models to build sustainable digital solutions.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/saigon-technology-why-businesses-fear-modernizing-software-in-the-ai-era-302927193.html

SOURCE Saigon Technology

Continue Reading

Technology

I AM ALS COMMUNITY CELEBRATES AS ACT FOR ALS BECOMES LAW AND MAKES HISTORY

Published

on

By

Community Advocates, Including Co-Founders Brian Wallach and Sandra Abrevaya and I AM ALS Ambassadors Late Actor Eric Dane and Former Pro Wrestler Tanea “Rebel” Brooks, Drive Landmark Win Securing Up to $500 Million in Funding and Therapy Access, and a Continued Path to a Cure

Download Photos/Logo Here
I AM ALS Celebration Video for ACT for ALS

WASHINGTON, Nov. 3, 2026 /PRNewswire/ — I AM ALS and its national force of advocates are celebrating as the President signed the ACT for ALS reauthorization bill into law. This comes after the Senate approved the bill by unanimous consent with just hours left until the law expired, even after the House went home early. The I AM ALS community first identified a major gap in access to investigational treatments and co-authored the original ACT for ALS Act to address it in 2021. Now, with years of success underway, the law has five more years to scale research infrastructure and treatment access, representing an investment of up to an additional $500 million for ALS.

“Over the past 7+ years, this community has changed what’s possible in ALS,” said I AM ALS co-founder Brian Wallach. “The I AM ALS community’s leadership has brought us closer than ever to a cure by unlocking over $2 billion for federal ALS research, expanding and protecting access to life-changing therapies, and accelerating scientific breakthroughs. We thank our ALS congressional champions—including sponsors Senators Coons (D-DE) and Murkowski (R-AK) and Representatives Quigley (D-IL-05) and Calvert (R-CA-41)—and all the tireless advocates who helped renew this historic legislation for five more years.”

Today’s law passage is groundbreaking and thanks to the significant efforts of I AM ALS’ community-led movement. Since ACT for ALS was first signed into law, I AM ALS has monitored and reported on the ground-breaking success of its implementation. Leading into the reauthorization year, I AM ALS built and deployed a comprehensive, multi-pronged advocacy campaign, including:

Building and strengthening relationships with Congressional champions,Deploying a vast grassroots army of volunteer leaders from across the country,Partnering with researchers, other organizations, and celebrity ambassadors—most notably the late actor Eric Dane and professional wrestler Tanea “Rebel” Brooks—to strengthen and amplify our message, andEngaging with top experts in government affairs and public relations.

This year alone, I AM ALS held more than 430 in-person and virtual advocacy meetings and calls, secured more than 38,000 online actions, sent more than 95,000 emails, and gathered more than 20,100 petition signatures in the final weeks before expiration.

Unlike any other legislation the neurodegenerative landscape has ever seen, ACT for ALS has already invested hundreds of millions of dollars into ALS research, provided investigational therapy access for more than 800 patients who would not otherwise have qualified, and built lasting infrastructure for future learnings.

“These past months didn’t just get a critical bill passed; they inspired a community that continually renews itself, welcomes new advocates, develops new leaders, and ensures that every generation is ready to fight for the next breakthrough,” said Troy Fields, volunteer co-chair of the I AM ALS legislative affairs team, and person living with ALS. “ALS is relentless, but we continue to prove so are we.”

“For the past five years, the ACT for ALS has advanced scientific research and helped people with ALS access the promising treatments they need. This reauthorization of the bill continues that work and lends hope to a future where there is a cure for ALS,” said Congressman Quigley. “I’m glad this important bill was signed into law, and I’m thankful to my colleagues in both the House and the Senate for getting this done.”

“I’m thrilled that the ACT for ALS Reauthorization Act has been signed into law, renewing our commitment to finding cures and treatments for ALS,” said Rep. Calvert. “As a Co-Chair of the bipartisan ALS Caucus, I know just how hard those impacted by ALS have worked to get this bill enacted and I applaud their tireless advocacy. With the ACT for ALS Reauthorization Act officially signed into law, we celebrate this victory while remaining focused on the work ahead to end this terrible disease.”

I AM ALS is calling on supporters to thank the Congressional champions who helped make this law possible at bit.ly/A4A-TY 

About I AM ALS

I AM ALS is a nonprofit organization leading what STAT News called the most successful patient advocacy campaign this century. We built a community movement to harness collective power and find treatments and a cure for ALS faster, while also creating lasting, systemic change. Our focus is on three areas:

Advocating for federal policy change to drive research, support, and treatments for ALS.Improving quality of life by providing volunteer and support opportunities to advocates and people living with ALS.Mobilizing and empowering advocates to raise awareness about ALS and other neurodegenerative diseases, and increase visibility of the ALS experience.

Learn more at www.iamals.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-am-als-community-celebrates-as-act-for-als-becomes-law-and-makes-history-302928523.html

SOURCE I AM ALS

Continue Reading

Technology

Atomic Mobile unveils multi-carrier IoT service connecting devices across the globe

Published

on

By

SPRING LAKE, N.J., Nov. 3, 2026 /PRNewswire/ — Atomic Mobile today introduced Atomic Orbit , a cellular internet service designed to maintain connectivity for IoT devices by utilizing multiple carrier networks. The service addresses the critical need for reliable data access in scanners, tablets, POS terminals, and smart meters that frequently move across varying signal environments. Atomic Orbit offers global reach across hundreds of operators worldwide.

Relying on a single carrier often leads to coverage gaps, especially for mobile assets or devices deployed in diverse geographic regions. Atomic Orbit solves this by providing access to three national carriers and 18 regional carriers within the United States, alongside global multi-carrier support. This architecture ensures that devices automatically switch to the strongest available signal, maintaining uptime for essential business operations. By eliminating the limitations of a single-provider model, the platform enables enterprises to deploy devices globally without the risk of localized dead zones.

Aaron Ogden, VP of of Customer Success, says “Over the years, I’ve worked across finance, energy, education, logistics, and healthcare, and I’ve seen how much day-to-day operations depend on reliable connectivity. Whether it’s a payment terminal processing a sale, a remote utility sensor reporting a reading, a fleet tracker sending its location, a field technician pulling up a work order on a tablet, or a backup solution, the connection matters wherever the work happens. A multi-carrier SIM gives organizations access to more than one network, helping keep devices connected as they move between locations or when coverage varies or fails.”

The implementation of eSIM technology further simplifies logistics, allowing enterprises to manage profits by reducing the operational complexity of physical hardware swaps when changing service plans or carriers. This flexibility is critical for organizations looking to scale their IoT footprint without increasing administrative overhead.

Core functionality

Network Agility: SIMs automatically transition between networks to secure the most robust connection available.Scalable Management: A centralized platform and API allow for bulk SIM management and the activation of both physical SIMs and eSIMs.Operational Transparency: Comprehensive audit logs track all modifications to SIM status, while integrated support ticketing systems streamline troubleshooting.

Learn more about Atomic Orbit at https://atomicmobile.com/products/orbit .

Atomic Mobile developed the product in response to direct requests from customers seeking a reliable multi-carrier service for connected devices both in domestic and international markets. The service is available now for enterprises requiring high-availability mobile connectivity. 

Media Contact:
Atomic Mobile
info@atomicmobile.com
www.atomicmobile.com

About Atomic Mobile
Atomic Mobile provides mobile connectivity and enablement solutions to MVNOs and enterprises worldwide. With a focus on reliability, transparency, and scalability, the company empowers its customers with comprehensive solutions across network services, usage visibility, billing, compliance, and customer operations.

View original content to download multimedia:https://www.prnewswire.com/news-releases/atomic-mobile-unveils-multi-carrier-iot-service-connecting-devices-across-the-globe-302928539.html

SOURCE Atomic Mobile

Continue Reading

Trending